Tolazamide, TolbutamideAlpha-glucosidase inhibitors Acarbose, Miglitol, VogliboseThiazolidinediones (TZD) Pioglitazone, Rivoglitazone†, Rosiglitazone, Troglitazone‡Meglitinides amaryl class action Repaglinide, MitiglinideDipeptidyl peptidase-4 (DPP-4) inhibitors Alogliptin,† Saxagliptin,† Sitagliptin.

or sources. (November 2007)Please help improve this article by adding citations to reliable sources. Unverifiable amaryl class action may be challenged and removed.GlimepirideSystematic (IUPAC) name3-ethyl-N,N-bis (3-ethyl-4-methyl-2-oxo-5H-pyrrol-2-yl)- 4-methyl-2-oxo-5H-pyrrole-1- carboxamideIdentifiersCAS number 93479-97-1ATC code A10BB12PubChem 3476DrugBank APRD00381Chemical dataFormula C24H34N4O5SMol. mass 490.617 g/molPharmacokinetic dataBioavailability ?Protein binding >99.5%Metabolism ?Half life ?Excretion ?Therapeutic considerationsPregnancy cat. ?Legal statusRoutes ?Glimepiride is a medium-to-long amaryl class action sulfonylurea anti-diabetic drug. amaryl class action is marketed as Amaryl by Sanofi-Aventis. Glimepiride is the first third-generation sulfonylurea, and is very potent.Contents amaryl class action Indications2 Adverse effects3 Contraindications4 Interactions5 Pharmacology6 amaryl class action amaryl class action action[edit] IndicationsType 2 diabetes (NIDDM).[edit] Adverse effectsMain article: SulfonylureaGI disturbance, rarely thrombopenia , leucopenia, haemolytic.

(TZD) Pioglitazone, Rivoglitazone†, Rosiglitazone, Troglitazone‡Meglitinides Nateglinide.